AbbVie Inc. $ABBV Shares Sold by Summit Investment Advisors Inc.

Summit Investment Advisors Inc. trimmed its holdings in AbbVie Inc. (NYSE:ABBV) by 2.6% during the first quarter, Holdings Channel reports. The institutional investor owned 53,275 shares of the company’s stock after selling 1,435 shares during the period. Summit Investment Advisors Inc.’s holdings in AbbVie were worth $11,162,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Brighton Jones LLC boosted its holdings in AbbVie by 17.4% in the fourth quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock valued at $4,072,000 after acquiring an additional 3,401 shares during the last quarter. Revolve Wealth Partners LLC lifted its stake in shares of AbbVie by 72.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock valued at $1,294,000 after purchasing an additional 3,064 shares in the last quarter. Financial Gravity Asset Management Inc. purchased a new stake in shares of AbbVie during the 1st quarter worth about $59,000. Phillips Financial Management LLC increased its position in AbbVie by 4.1% during the 1st quarter. Phillips Financial Management LLC now owns 2,952 shares of the company’s stock worth $619,000 after purchasing an additional 117 shares in the last quarter. Finally, Cerity Partners LLC raised its holdings in AbbVie by 12.0% in the first quarter. Cerity Partners LLC now owns 979,028 shares of the company’s stock valued at $205,126,000 after buying an additional 105,110 shares during the period. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other AbbVie news, EVP Azita Saleki-Gerhardt sold 42,370 shares of the company’s stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $198.42, for a total value of $8,407,055.40. Following the transaction, the executive vice president owned 177,292 shares of the company’s stock, valued at approximately $35,178,278.64. This represents a 19.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.25% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on ABBV shares. UBS Group raised their target price on shares of AbbVie from $195.00 to $220.00 and gave the company a “neutral” rating in a research note on Friday. Berenberg Bank upgraded AbbVie from a “hold” rating to a “buy” rating and raised their target price for the company from $170.00 to $270.00 in a report on Wednesday, September 17th. Daiwa America raised shares of AbbVie from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 7th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of AbbVie in a research note on Wednesday, October 8th. Finally, BMO Capital Markets boosted their price objective on shares of AbbVie from $215.00 to $240.00 and gave the stock an “outperform” rating in a report on Friday, September 12th. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $236.57.

AbbVie Stock Performance

Shares of ABBV stock opened at $218.92 on Friday. The stock has a market capitalization of $386.74 billion, a price-to-earnings ratio of 104.25, a PEG ratio of 1.42 and a beta of 0.50. AbbVie Inc. has a one year low of $163.81 and a one year high of $244.81. The company’s 50-day simple moving average is $223.24 and its 200-day simple moving average is $202.30. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.61 and a current ratio of 0.74.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. The company had revenue of $15.78 billion for the quarter, compared to the consensus estimate of $15.58 billion. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.AbbVie’s quarterly revenue was up 9.1% compared to the same quarter last year. During the same quarter last year, the business posted $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Equities analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be given a dividend of $1.73 per share. This is a boost from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. This represents a $6.92 annualized dividend and a dividend yield of 3.2%. AbbVie’s payout ratio is 524.24%.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.